eXCELL Biotherapeutics Inc.
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
eXCELL is an immunotherapy company that uses the body built-in immune rejection responses to non-self cells to combat the difficult-to-treat cancers by utilizing xenogeneic cells that could promote cancer immunity cycle due to the similarities between xenogeneic cells and tumor cells.
Founded Year
2019
Unified Business No.
82820364
Status
Active
Number of Employees
6
Total Paid-in
Capital
47,533,330 (NT$)
Location of Company
Taiwan
, Taichung City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
To discover, develop, and diver transformative xenogeneic cellular medicines to cancer patients and improve their outcomes. eXCELL is a company dedicated to developing revolutionary therapies to meliorate people’s lives.
